$AARD

Aardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/Roche SAN

Aardvark Therapeutics (NASDAQ:AARD) appointed David Zhang, Ph.D., MBA, to its board of directors. Zhang has 25+ years of experience in clinical strategy and biostatistics, previously working at Abivax, Alumis, MyoKardia, and Roche. Aardvark is a clinical-stage biopharmaceutical company focused on Prader-Willi Syndrome and metabolic diseases.

Aardvark Therapeutics (NASDAQ:AARD) COO Nelson Sun sold 76,754 shares for $394,957 between September 10-11, 2026, at prices ranging from $5.0006 to $5.1803. The stock is down 61% year-to-date, trading at $5.13. Sun now holds 35,475 shares, including 3,745 from the 2025 ESPP. Sales were under a 10b5-1 plan.

Aardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 14, 2026, Aardvark Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 21,884,158 shares of the Company’s common stock outstanding as of June 18, 20

Aardvark Therapeutics (AARD) reported Q2 2026 results and updates on ARD-101 in Prader-Willi syndrome. The FDA placed a full clinical hold on the IND in May 2026, covering the Phase 3 HERO and OLE trials, which the company terminated in June 2026. Aardvark plans a Q3 2026 review of unblinded data. Q2 R&D was $10.5M, net loss $14.4M, and cash was $73.9M.

Aardvark Therapeutics (AARD) shares rose 11.1% in pre-open after the company reported Q2 2026 results on Aug. 11. According to the article, EPS beat expectations by $0.21 versus consensus of -$0.88. Aardvark reported $73.9M cash and said it remains in active FDA discussions to resolve the ARD-101 clinical hold.

Aardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps Remains in active discus

Aardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001774857 0001774857 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,

Bank of America Securities analyst Tazeen Ahmad downgraded Aardvark Therapeutics to a Sell rating and slashed its price target from $18 to $4. This downgrade is due to an FDA clinical hold on the company's lead program, ARD-101, following cardiac issues in trials. Increased regulatory hurdles and growing competition from other treatments for Prader-Willi syndrome also contributed to the revised outlook.

Aardvark Therapeutics announced that the FDA has placed a full clinical hold on its investigational new drug application (IND) for ARD-101, impacting its Phase 3 HERO trial and open-label extension trial for Prader-Willi Syndrome. The company plans to unblind clinical data from both trials to inform the next steps for its ARD-101 program while engaging with the FDA to resolve the hold. Aardvark currently has $91.2 million in cash equivalents, which is expected to fund operations into mid-2027.